

## Datasheet: HCA315

**BATCH NUMBER 148473**

<b>Description:</b>	HUMAN ANTI ECULIZUMAB
<b>Specificity:</b>	ECULIZUMAB
<b>Format:</b>	Purified
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	AbD32109_hlgG1
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	0.1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

<b>Product Form</b>	Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
<b>Preparation</b>	Purified IgG prepared by affinity chromatography on Protein A
<b>Buffer Solution</b>	Phosphate buffered saline
<b>Preservative Stabilisers</b>	0.01% Thiomersal
<b>Approx. Protein Concentrations</b>	Antibody concentration 0.5 mg/ml
<b>Immunogen</b>	Eculizumab

### Specificity

**Human Anti-Eculizumab Antibody, clone AbD32109\_hlgG1** is a paratope specific, inhibitory anti-idiotypic antibody that specifically recognizes the free humanized monoclonal antibody eculizumab. It does not recognize free human complement C5 or

eculizumab in complex with C5.

Clone AbD32109\_hlgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a surrogate positive control or calibrator in an anti-drug antibody (ADA) assay as part of eculizumab or biosimilar immunogenicity testing.

Eculizumab (Soliris) is a humanized IgG2/4 kappa antibody. The heavy chains are comprised of human IgG2 sequences in CH1, the hinge and the adjacent portion CH2, and human IgG4 sequences in the remaining part of CH2 and CH3. The drug is used to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired life-threatening disease of the blood characterized by destruction of red blood cells by the complement system. It also has approval as an orphan drug for treatment of atypical hemolytic uremic syndrome (aHUS). Eculizumab specifically binds to the terminal complement component 5 (C5) and inhibits the cleavage of C5 to C5a and C5b by the C5 convertase, which prevents the generation of the terminal complement complex C5b-9. Both C5a and C5b-9 cause the terminal complement-mediated events that are characteristic of PNH and aHUS. A 1:1 molar ratio of eculizumab to C5 is sufficient for C5 inhibition.

[View a summary of all anti-eculizumab antibodies](#)

---

<b>Affinity</b>	The monovalent intrinsic affinity of AbD32109_hlgG1 was measured as $K_D = 3$ nM by real time, label free molecular interaction analysis on immobilized eculizumab.
-----------------	---

---

<b>ELISA</b>	Clone AbD32109_hlgG1 can be used in an indirect ELISA. It can also be used as a surrogate positive control or calibrator in an anti-drug antibody assay.
--------------	--

Protocol: [Anti-Drug Antibody bridging ELISA](#)

---

<b>Storage</b>	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
----------------	---

---

<b>Guarantee</b>	12 months from date of despatch
------------------	---------------------------------

---

<b>Acknowledgements</b>	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Soliris is a trademark of Alexion Pharmaceuticals, Inc.
-------------------------	--

---

<b>Health And Safety Information</b>	Material Safety Datasheet documentation #10094 available at: <a href="https://www.bio-rad-antibodies.com/SDS/HCA315">https://www.bio-rad-antibodies.com/SDS/HCA315</a> 10094
--------------------------------------	--

---

<b>Licensed Use</b>	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
---------------------	---

---

---

**Regulatory** For research purposes only

---

**Technical Advice** Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#)

---

## Related Products

### Recommended Useful Reagents

[HUMAN ANTI ECULIZUMAB \(HCA312\)](#)

[HUMAN ANTI ECULIZUMAB \(HCA313\)](#)

[HUMAN ANTI ECULIZUMAB \(HCA314\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)

'M371772:200612'

**Printed on 25 Mar 2023**

---

© 2023 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)